Open access · CC-BY
via OpenAlex
Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia
Wing-Hang Tong, Hayden Ollivierre, Audrey C. Noguchi, Manik Chandra Ghosh, Danielle Springer, Tracey Ann Rouault
Heliyon · 2021 · ▲ 8 citations
Deregulated nutrient-sensing
Mitochondrial dysfunction
Altered intercellular communication
Rapamycin / mTOR inhibition
Cell culture / in vitro
Human
Mouse
Abstract
Cardiomyopathy is a primary cause of death in Friedreich ataxia (FRDA) patients with defective iron-sulfur cluster (ISC) biogenesis due to loss of functional frataxin and in rare patients with functional loss of other ISC biogenesis factors. The mechanistic target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) (mTOR) and AKT signaling cascades that coordinate eukaryotic cell growth and metabolism with environmental inputs, including nutrients and growth factors, are crucial regulators of cardiovascular growth and homeostasis. We observed increased phosphorylation of AKT and dysregulation of multiple downstream effectors of mTORC1, including S6K1, S6, ULK1 and 4EBP1, in a cardiac/skeletal muscle specific FRDA conditional knockout (cKO) mouse model and in human cell lines depleted of ISC biogenesis factors. Knockdown of several mitochondrial metabolic proteins that are downstream targets of ISC biogenesis, including lipoyl synthase and subunit B of succinate dehydrogenase, also resulted in activation of mTOR and AKT signaling, suggesting that mTOR and AKT hyperactivations are part of the metabolic stress response to ISC deficiencies. Administration of rapamycin, a specific inhibitor of mTOR signaling, enhanced the survival of the Fxn cKO mice, providing proof of concept for the potential of mTOR inhibition to ameliorate cardiac disease in patients with defective ISC biogenesis. However, AKT phosphorylation remained high in rapamycin-treated Fxn cKO hearts, suggesting that parallel mTOR and AKT inhibition might be necessary to further improve the lifespan and healthspan(definition) of ISC deficient individuals.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.heliyon.2022.e10371
- Canonical
- link ↗
- Fetched
- 2026-11-07 MST
Cite this
APA
Tong, W., Ollivierre, H., Noguchi, A.C., Ghosh, M.C., Springer, D., & Rouault, T.A. (2021). Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia. <em>Heliyon</em>. https://doi.org/10.1016/j.heliyon.2022.e10371
Vancouver
Tong W, Ollivierre H, Noguchi AC, Ghosh MC, Springer D, Rouault TA. Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia. Heliyon. 2021. doi:10.1016/j.heliyon.2022.e10371.
BibTeX
@article{winghang2021Hypera,
title = {Hyperactivation of mTOR and AKT in a cardiac hypertrophy animal model of Friedreich ataxia},
author = {Wing-Hang Tong and Hayden Ollivierre and Audrey C. Noguchi and Manik Chandra Ghosh and Danielle Springer and Tracey Ann Rouault},
journal = {Heliyon},
year = {2021},
doi = {10.1016/j.heliyon.2022.e10371},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
MedComm – Future Medicine 2022
Open access · CC-BY
Dysbiosis of gut microbiome contributes to glaucoma pathogenesis
Journal for ImmunoTherapy of Cancer 2019
Open access · CC-BY
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
Signal Transduction and Targeted Therapy 2023
Open access · CC-BY
Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease
Circulation 2017
Open access · OA
Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy
BMB Reports 2011
Open access · CC-BY
The functions of mTOR in ischemic diseases
International Journal of Molecular Sciences 2021
Open access · CC-BY